Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Gabor Halmos

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Anatomy

Cultured Tumor Cells

Procedures

Physiology

Cell Division

Disorders

Prostatic Neoplasms

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
143
Schally, Andrew
63
Groot, Kate
53
Nagy, Attila
53
Szepeshazi, Karoly
31
Varga, Jozsef
27
Pinski, Jacek
25
Armatis, Patricia
18
Zarandi, Marta
15
Engel, Jörg
15
Plonowski, Artur
14
Keller, Gunhild
12
Cai, Renzhi
11
Hebert, Francine
10
Arencibia, Jose
10
Baker, Ben

Sign-in to see all Coauthors

Publications

TOP 3
Rózsa Bernadett; Juhász Aliz; Treszl Andrea; Tóth György; Flaskó Tibor; Dezsö Balázs; Block Norman L; Schally Andrew V; Halmos Gábor
Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.
Hohla Florian; Buchholz Stefan; Schally Andrew V; Seitz Stefan; Rick Ferenc G; Szalontay Luca; Varga Jozsef L; Zarandi Marta; Halmos Gabor; Vidaurre Irving; Krishan Awtar; Kurtoglu Metin; Chandna Sudhir; Aigner Elmar; Datz Christian
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Treszl Andrea; Schally Andrew V; Seitz Stephan; Szalontay Luca; Rick Ferenc G; Szepeshazi Karoly; Halmos Gabor
Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Gabor Halmos (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Rózsa Bernadett; Juhász Aliz; Treszl Andrea; Tóth György; Flaskó Tibor; Dezsö Balázs; Block Norman L; Schally Andrew V; Halmos Gábor
Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.
International journal of oncology 2009;35(5):1053-9.
2009: Hohla Florian; Buchholz Stefan; Schally Andrew V; Seitz Stefan; Rick Ferenc G; Szalontay Luca; Varga Jozsef L; Zarandi Marta; Halmos Gabor; Vidaurre Irving; Krishan Awtar; Kurtoglu Metin; Chandna Sudhir; Aigner Elmar; Datz Christian
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Cell cycle (Georgetown, Tex.) 2009;8(19):3149-56.
2009: Treszl Andrea; Schally Andrew V; Seitz Stephan; Szalontay Luca; Rick Ferenc G; Szepeshazi Karoly; Halmos Gabor
Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Peptides 2009;30(9):1643-50.
2009: Seitz Stephan; Schally Andrew V; Treszl Andrea; Papadia Andrea; Rick Ferenc; Szalontay Luca; Szepeshazi Karoly; Ortmann Olaf; Halmos Gabor; Hohla Florian; Buchholz Stefan
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anti-cancer drugs 2009;20(7):553-8.
2008: Heinrich Elmar; Schally Andrew V; Buchholz Stefan; Rick Ferenc G; Halmos Gabor; Mile Melinda; Groot Kate; Hohla Florian; Zarandi Marta; Varga Jozsef L
Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
The Prostate 2008;68(16):1763-72.
2008: Szepeshazi Karoly; Schally Andrew V; Treszl Andrea; Seitz Stephan; Halmos Gabor
Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Anti-cancer drugs 2008;19(4):349-58.
2007: Hohla Florian; Schally Andrew V; Kanashiro Celia A; Buchholz Stefan; Baker Benjamin; Kannadka Chandrika; Moder Angelika; Aigner Elmar; Datz Christian; Halmos Gabor
Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(47):18671-6.
2007: Stangelberger Anton; Schally Andrew V; Zarandi Marta; Heinrich Elmar; Groot Kate; Havt Alexandre; Kanashiro Celia A; Varga Jozsef L; Halmos Gabor
The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
The Prostate 2007;67(12):1339-53.
2007: Szepeshazi Karoly; Schally Andrew V; Halmos Gabor
LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
International journal of oncology 2007;30(6):1485-92.
2007: Buchholz Stefan; Schally Andrew V; Engel Jörg B; Hohla Florian; Heinrich Elmar; Koester Frank; Varga Jozsef L; Halmos Gabor
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(6):1943-6.
2006: Hohla Florian; Schally Andrew V; Szepeshazi Karoly; Varga Jozsef L; Buchholz Stefan; Köster Frank; Heinrich Elmar; Halmos Gabor; Rick Ferenc G; Kannadka Chandrika; Datz Christian; Kanashiro Celia A
Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(39):14513-8.
2006: Buchholz Stefan; Keller Gunhild; Schally Andrew V; Halmos Gabor; Hohla Florian; Heinrich Elmar; Koester Frank; Baker Benjamin; Engel Jörg B
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(27):10403-7.
2006: Keller Gunhild; Schally Andrew V; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
International journal of oncology 2006;28(6):1507-13.
2006: Zarandi Marta; Varga Jozsef L; Schally Andrew V; Horvath Judit E; Toller Gabor L; Kovacs Magdolna; Letsch Markus; Groot Kate; Armatis Patricia; Halmos Gabor
Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(12):4610-5.
2006: Stangelberger Anton; Schally Andrew V; Nagy Attila; Szepeshazi Karoly; Kanashiro Celia A; Halmos Gabor
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
The Prostate 2006;66(2):200-10.
2006: Stangelberger Anton; Schally Andrew V; Letsch Markus; Szepeshazi Karoly; Nagy Attila; Halmos Gabor; Kanashiro Celia A; Corey Eva; Vessella Robert
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
International journal of cancer. Journal international du cancer 2006;118(1):222-9.
2005: Engel Jörg B; Schally Andrew V; Halmos Gabor; Baker Benjamin; Nagy Attila; Keller Gunhild
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Endocrine-related cancer 2005;12(4):999-1009.
2005: Havt Alexandre; Schally Andrew V; Halmos Gabor; Varga Jozsef L; Toller Gabor L; Horvath Judit E; Szepeshazi Karoly; Köster Frank; Kovitz Kevin; Groot Kate; Zarandi Marta; Kanashiro Celia A
The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(48):17424-9.
2005: Keller Gunhild; Schally Andrew V; Nagy Attila; Halmos Gabor; Baker Benjamin; Engel Jorg B
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Cancer 2005;104(10):2266-74.
2005: Szepeshazi Karoly; Schally Andrew V; Nagy Attila; Halmos Gabor
Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog.
Pancreas 2005;31(3):275-82.
2005: Keller Gunhild; Schally Andrew V; Gaiser Timo; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
European journal of cancer (Oxford, England : 1990) 2005;41(14):2196-202.
2005: Engel Jorg B; Schally Andrew V; Halmos Gabor; Baker Ben; Nagy Attila; Keller Gunhild
Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Cancer 2005;104(6):1312-21.
2005: Keller Gunhild; Schally Andrew V; Gaiser Timo; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5549-57.
2005: Engel Jörg B; Schally Andrew V; Halmos Gabor; Baker Benjamin; Nagy Attila; Keller Gunhild
Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
European journal of cancer (Oxford, England : 1990) 2005;41(12):1824-30.
2005: Kanashiro Celia A; Schally Andrew V; Varga Jozsef L; Hammann Brian; Halmos Gabor; Zarandi Marta
Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.
Cancer letters 2005;226(2):123-31.
2005: Stangelberger Anton; Schally Andrew V; Varga Jozsef L; Hammann Brian D; Groot Kate; Halmos Gabor; Cai Ren-Zhi; Zarandi Marta
Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
The Prostate 2005;64(3):303-15.
2005: Keller Gunhild; Schally Andrew V; Groot Kate; Toller Gabor L; Havt Alexandre; Köster Frank; Armatis Patricia; Halmos Gabor; Zarandi Marta; Varga Jozsef L; Engel Jörg B
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(30):10628-33.
2005: Keller Gunhild; Schally Andrew V; Gaiser Timo; Nagy Attila; Baker Benjamin; Westphal Gabriela; Halmos Gabor; Engel Jörg B
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Cancer research 2005;65(13):5857-63.
2005: Kanashiro Celia A; Schally Andrew V; Nagy Attila; Halmos Gabor
Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms.
International journal of oncology 2005;27(1):169-74.
2005: Engel Jörg B; Keller Gunhild; Schally Andrew V; Toller Gabor L; Groot Kate; Havt Alexandre; Armatis Patricia; Zarandi Marta; Varga Jozsef L; Halmos Gabor
Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
The Journal of clinical endocrinology and metabolism 2005;90(6):3614-21.
2005: Keller Gunhild; Engel Jörg B; Schally Andrew V; Nagy Attila; Hammann Brian; Halmos Gabor
Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
International journal of cancer. Journal international du cancer 2005;114(5):831-5.
2005: Engel Jörg B; Keller Gunhild; Schally Andrew V; Nagy Attila; Chism David D; Halmos Gabor
Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Fertility and sterility 2005;83 Suppl 1():1125-33.
2005: Engel Jörg B; Keller Gunhild; Schally Andrew V; Halmos Gabor; Hammann Brian; Nagy Attila
Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2408-15.
2005: Kanashiro Celia A; Schally Andrew V; Cai R-Z; Halmos Gabor
Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma.
Anti-cancer drugs 2005;16(2):159-65.
2005: Stangelberger Anton; Schally Andrew V; Varga Jozsef L; Zarandi Marta; Szepeshazi Karoly; Armatis Patricia; Halmos Gabor
Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):49-57.
2004: Toller Gabor L; Horvath Judit E; Schally Andrew V; Halmos Gabor; Varga Jozsef L; Groot Kate; Chism David; Zarandi Marta
Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(42):15160-5.
2004: Schally A V; Szepeshazi K; Nagy A; Comaru-Schally A M; Halmos G
New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.
Cellular and molecular life sciences : CMLS 2004;61(9):1042-68.
2004: Varga Jozsef L; Schally Andrew V; Horvath Judit E; Kovacs Magdolna; Halmos Gabor; Groot Kate; Toller Gabor L; Rekasi Zoltan; Zarandi Marta
Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(6):1708-13.
2004: Letsch Markus; Schally Andrew V; Szepeshazi Karoly; Halmos Gabor; Nagy Attilla
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
The Journal of urology 2004;171(2 Pt 1):911-5.
2003: Szereday Zoltan; Schally Andrew V; Varga Jozsef L; Kanashiro Celia A; Hebert Francine; Armatis Patricia; Groot Kate; Szepeshazi Karoly; Halmos Gabor; Busto Rebeca
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
Cancer research 2003;63(22):7913-9.
2003: Letsch Markus; Schally Andrew V; Szepeshazi Karoly; Halmos Gabor; Nagy Attila
Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4505-13.
2003: Szepeshazi Karoly; Schally Andrew V; Nagy Attila; Wagner Brady W; Bajo Ana Maria; Halmos Gabor
Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Cancer 2003;98(7):1401-10.
2003: Bajo Ana M; Schally Andrew V; Halmos Gabor; Nagy Attila
Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3742-8.
2003: Kiaris Hippokratis; Chatzistamou Ioulia; Schally Andrew V; Halmos Gabor; Varga Jozsef L; Koutselini Helen; Kalofoutis Anastasios
Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(16):9512-7.
2003: Szereday Zoltan; Schally Andrew V; Szepeshazi Karoly; Bajo Ana-Maria; Hebert Francine; Halmos Gabor; Nagy Attila
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
International journal of oncology 2003;22(5):1141-6.
2003: Halmos Gabor; Schally Andrew V; Comaru-Schally Ana Maria; Nagy Attila; Irimpen Anand
Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium.
Life sciences 2003;72(23):2669-74.
2002: Halmos Gabor; Schally Andrew V; Czompoly Tamas; Krupa Magdalena; Varga Jozsef L; Rekasi Zoltan
Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
The Journal of clinical endocrinology and metabolism 2002;87(10):4707-14.
2002: Plonowski Artur; Schally Andrew V; Busto Rebeca; Krupa Magdalena; Varga Jozsef L; Halmos Gabor
Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.
Peptides 2002;23(6):1127-33.
2002: Szereday Z; Schally A V; Nagy A; Plonowski A; Bajo A M; Halmos G; Szepeshazi K; Groot K
Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.
British journal of cancer 2002;86(8):1322-7.
2002: Plonowski Artur; Varga Jozsef L; Schally Andrew V; Krupa Magdalena; Groot Kate; Halmos Gabor
Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
International journal of cancer. Journal international du cancer 2002;98(4):624-9.
2002: Szepeshazi Karoly; Schally Andrew V; Halmos Gabor; Armatis Patricia; Hebert Francine; Sun Baodong; Feil Anita; Kiaris Hippokratis; Nagy Attila
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Cancer research 2002;62(3):781-8.
2002: Plonowski Artur; Schally Andrew V; Nagy Attila; Sun Baodong; Halmos Gabor
Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
International journal of oncology 2002;20(2):397-402.
2002: Halmos Gabor; Schally Andrew V
Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(2):961-5.
2001: Chatzistamou I; Schally A V; Varga J L; Groot K; Busto R; Armatis P; Halmos G
Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone.
Anti-cancer drugs 2001;12(9):761-8.
2001: Schally A V; Comaru-Schally A M; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga J L; Halmos G
Hypothalamic hormones and cancer.
Frontiers in neuroendocrinology 2001;22(4):248-91.
2001: Szepeshazi K; Schally A V; Armatis P; Groot K; Hebert F; Feil A; Varga J L; Halmos G
Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.
Endocrinology 2001;142(10):4371-8.
2001: Plonowski A; Schally A V; Koppan M; Nagy A; Arencibia J M; Csernus B; Halmos G
Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.
Cancer 2001;92(5):1168-76.
2001: Szepeshazi K; Schally A V; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2854-61.
2001: Rekasi Z; Varga J L; Schally A V; Plonowski A; Halmos G; Csernus B; Armatis P; Groot K
Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways.
Peptides 2001;22(6):879-86.
2001: Chatzistamou I; Schally A V; Varga J L; Groot K; Armatis P; Busto R; Halmos G
Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
The Journal of clinical endocrinology and metabolism 2001;86(5):2144-52.
2001: Kiaris H; Schally A V; Nagy A; Szepeshazi K; Hebert F; Halmos G
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
European journal of cancer (Oxford, England : 1990) 2001;37(5):620-8.
2001: Arencibia J M; Schally A V; Halmos G; Nagy A; Kiaris H
In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
Anti-cancer drugs 2001;12(1):71-8.
2000: Plonowski A; Nagy A; Schally A V; Sun B; Groot K; Halmos G
In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
International journal of cancer. Journal international du cancer 2000;88(4):652-7.
2000: Halmos G; Sun B; Schally A V; Hebert F; Nagy A
Human ovarian cancers express somatostatin receptors.
The Journal of clinical endocrinology and metabolism 2000;85(10):3509-12.
2000: Chatzistamou L; Schally A V; Nagy A; Armatis P; Szepeshazi K; Halmos G
Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4158-65.
2000: Schally A V; Comaru-Schally A M; Plonowski A; Nagy A; Halmos G; Rekasi Z
Peptide analogs in the therapy of prostate cancer.
The Prostate 2000;45(2):158-66.
2000: Rekasi Z; Czompoly T; Schally A V; Halmos G
Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(19):10561-6.
2000: Halmos G; Schally A V; Varga J L; Plonowski A; Rekasi Z; Czompoly T
Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(19):10555-60.
2000: Halmos G; Schally A V; Kahan Z
Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
International journal of oncology 2000;17(2):367-73.
2000: Halmos G; Schally A V; Sun B; Davis R; Bostwick D G; Plonowski A
High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.
The Journal of clinical endocrinology and metabolism 2000;85(7):2564-71.
2000: Plonowski A; Schally A V; Varga J L; Rekasi Z; Hebert F; Halmos G; Groot K
Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
The Prostate 2000;44(2):172-80.
2000: Plonowski A; Schally A V; Nagy A; Kiaris H; Hebert F; Halmos G
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Cancer research 2000;60(11):2996-3001.
2000: Rekasi Z; Varga J L; Schally A V; Halmos G; Armatis P; Groot K; Czompoly T
Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Endocrinology 2000;141(6):2120-8.
2000: Sun B; Schally A V; Halmos G
The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers.
Regulatory peptides 2000;90(1-3):77-84.
2000: Szepeshazi K; Schally A V; Groot K; Armatis P; Halmos G; Herbert F; Szende B; Varga J L; Zarandi M
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.
British journal of cancer 2000;82(10):1724-31.
2000: Kahán Z; Varga J L; Schally A V; Rékási Z; Armatis P; Chatzistamou L; Czömpöly T; Halmos G
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
Breast cancer research and treatment 2000;60(1):71-9.
2000: Kahán Z; Sun B; Schally A V; Arencibia J M; Cai R Z; Groot K; Halmos G
Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Cancer 2000;88(6):1384-92.
2000: Sun B; Halmos G; Schally A V; Wang X; Martinez M
Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers.
The Prostate 2000;42(4):295-303.
2000: Kahán Z; Nagy A; Schally A V; Halmos G; Arencibia J M; Groot K
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Breast cancer research and treatment 2000;59(3):255-62.
2000: Kiaris H; Schally A V; Nagy A; Sun B; Szepeshazi K; Halmos G
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):709-17.
2000: Rekasi Z; Varga J L; Schally A V; Halmos G; Groot K; Czompoly T
Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(3):1218-23.
2000: Halmos G; Arencibia J M; Schally A V; Davis R; Bostwick D G
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
The Journal of urology 2000;163(2):623-9.
2000: Szepeshazi K; Schally A V; Groot K; Armatis P; Hebert F; Halmos G
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.
European journal of cancer (Oxford, England : 1990) 2000;36(1):128-36.
1999: Szepesházi K; Halmos G; Schally A V; Arencibia J M; Groot K; Vadillo-Buenfil M; Rodriguez-Martin E
Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
Journal of cancer research and clinical oncology 1999;125(8-9):444-52.
1999: Kahán Z; Nagy A; Schally A V; Hebert F; Sun B; Groot K; Halmos G
Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
International journal of cancer. Journal international du cancer 1999;82(4):592-8.
1999: Kahán Z; Nagy A; Schally A V; Halmos G; Arencibia J M; Groot K
Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Cancer 1999;85(12):2608-15.
1999: Miyazaki M; Schally A V; Nagy A; Lamharzi N; Halmos G; Szepeshazi K; Armatis P
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
American journal of obstetrics and gynecology 1999;180(5):1095-103.
1999: Halmos G; Nagy A; Lamharzi N; Schally A V
Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
Cancer letters 1999;136(2):129-36.
1999: Koppán M; Nagy A; Schally A V; Plonowski A; Halmos G; Arencibia J M; Groot K
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
The Prostate 1999;38(2):151-8.
1999: Varga J L; Schally A V; Csernus V J; Zarándi M; Halmos G; Groot K; Rékási Z
Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(2):692-7.
1998: Koppán M; Halmos G; Arencibia J M; Lamharzi N; Schally A V
Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
Cancer 1998;83(7):1335-43.
1998: Koppan M; Nagy A; Schally A V; Arencibia J M; Plonowski A; Halmos G
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Cancer research 1998;58(18):4132-7.
1998: Lamharzi N; Halmos G; Jungwirth A; Schally A V
Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
International journal of oncology 1998;13(3):429-35.
1998: Miyazaki M; Lamharzi N; Schally A V; Halmos G; Szepeshazi K; Groot K; Cai R Z
Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
European journal of cancer (Oxford, England : 1990) 1998;34(5):710-7.
1998: Jungwirth A; Schally A V; Halmos G; Groot K; Szepeshazi K; Pinski J; Armatis P
Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
Cancer 1998;82(5):909-17.
1998: Lamharzi N; Halmos G; Armatis P; Schally A V
Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines.
International journal of oncology 1998;12(3):671-5.
1998: Toth K; Kovacs M; Zarandi M; Halmos G; Groot K; Nagy A; Kele Z; Schally A V
New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.
The journal of peptide research : official journal of the American Peptide Society 1998;51(2):134-41.
1998: Nagy A; Schally A V; Halmos G; Armatis P; Cai R Z; Csernus V; Kovács M; Koppán M; Szepesházi K; Kahán Z
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1794-9.
1997: Miyazaki M; Nagy A; Schally A V; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
Journal of the National Cancer Institute 1997;89(23):1803-9.
1997: Szepeshazi K; Schally A V; Nagy A; Halmos G; Groot K
Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Anti-cancer drugs 1997;8(10):974-87.
1997: Szepeshazi K; Schally A V; Halmos G; Lamharzi N; Groot K; Horvath J E
A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(20):10913-8.
1997: Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai R Z; Groot K; Schally A V
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
The Prostate 1997;32(3):164-72.
1997: Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai R Z; Groot K; Vadillo-Buenfil M; Schally A V
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1141-8.
1997: Jungwirth A; Schally A V; Pinski J; Groot K; Armatis P; Halmos G
Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(11):5810-3.
1997: Halmos G; Schally A V
Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(3):956-60.
1997: Nagy A; Armatis P; Cai R Z; Szepeshazi K; Halmos G; Schally A V
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(2):652-6.
1997: Jungwirth A; Schally A V; Pinski J; Halmos G; Groot K; Armatis P; Vadillo-Buenfil M
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
British journal of cancer 1997;75(11):1585-92.
1997: Zarandi M; Kovacs M; Horvath J E; Toth K; Halmos G; Groot K; Nagy A; Kele Z; Schally A V
Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH).
Peptides 1997;18(3):423-30.
1996: Kovacs M; Zarándi M; Halmos G; Groot K; Schally A V
Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
Endocrinology 1996;137(12):5364-9.
1996: Kovács M; Halmos G; Groot K; Izdebski J; Schally A V
Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action.
Neuroendocrinology 1996;64(3):169-76.
1996: Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar S S; Schally A V
Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
Endocrinology 1996;137(8):3430-6.
1996: Nagy A; Schally A V; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(14):7269-73.
1996: Halmos G; Schally A V; Pinski J; Vadillo-Buenfil M; Groot K
Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(6):2398-402.
1996: Pinski J; Schally A V; Halmos G; Szepeshazi K; Groot K
Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice.
International journal of cancer. Journal international du cancer 1996;65(6):870-4.
1996: Szepeshazi K; Schally A V; Halmos G; Szoke B; Groot K; Nagy A
Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
Breast cancer research and treatment 1996;40(2):129-39.
1995: Pinski J; Schally A V; Groot K; Halmos G; Szepeshazi K; Zarandi M; Armatis P
Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.
Journal of the National Cancer Institute 1995;87(23):1787-94.
1995: Izdebski J; Pinski J; Horvath J E; Halmos G; Groot K; Schally A V
Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(11):4872-6.
1995: Halmos G; Wittliff J L; Schally A V
Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression.
Cancer research 1995;55(2):280-7.
1994: Zarandi M; Horvath J E; Halmos G; Pinski J; Nagy A; Groot K; Rekasi Z; Schally A V
Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(25):12298-302.
1994: Pinski J; Schally A V; Halmos G; Szepeshazi K; Groot K
Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
Cancer research 1994;54(22):5895-901.
1994: Pinski J; Schally A V; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai R Z
Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
British journal of cancer 1994;70(5):886-92.
1994: Pinski J; Reile H; Halmos G; Groot K; Schally A V
Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
International journal of cancer. Journal international du cancer 1994;59(1):51-5.
1994: Szepshazi K; Halmos G; Groot K; Schally A V
Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
International journal of pancreatology : official journal of the International Association of Pancreatology 1994;16(2-3):141-9.
1994: Halmos G; Pinski J; Szoke B; Schally A V
Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer.
Cancer letters 1994;85(1):111-8.
1994: Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally A V
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(15):7090-4.
1994: Pinski J; Halmos G; Yano T; Szepeshazi K; Qin Y; Ertl T; Schally A V
Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
International journal of cancer. Journal international du cancer 1994;57(4):574-80.
1994: Qin Y; Ertl T; Cai R Z; Halmos G; Schally A V
Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
Cancer research 1994;54(4):1035-41.
1994: Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally A V
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Cancer 1994;73(4):1229-38.
1994: Pinski J; Reile H; Halmos G; Groot K; Schally A V
Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Cancer research 1994;54(1):169-74.
1994: Qin Y; Halmos G; Cai R Z; Szoke B; Ertl T; Schally A V
Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
Journal of cancer research and clinical oncology 1994;120(9):519-28.
1994: Szöke B; Horváth J; Halmos G; Rékási Z; Groot K; Nagy A; Schally A V
LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro.
Peptides 1994;15(2):359-66.
1994: Radulovic S; Schally A V; Reile H; Halmos G; Szepeshazi K; Groot K; Milovanovic S; Miller G; Yano T
Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
Acta oncologica (Stockholm, Sweden) 1994;33(6):693-701.
1994: Szende B; Csikós A; Szepeshazi K; Neill J D; Mulchahey J J; Halmos G; Lapis K; Schally A V
The concentration of LH-RH receptors in the nuclei of pancreatic cancer cells. Effect of (D-Trp6)LH-RH on tumor-bearing Syrian golden hamsters.
Receptor 1994;4(4):201-7.
1994: Shirahige Y; Cai R Z; Szepeshazi K; Halmos G; Pinski J; Groot K; Schally A V
Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1994;48(10):465-72.
1994: O'Byrne K J; Halmos G; Pinski J; Groot K; Szepeshazi K; Schally A V; Carney D N
Somatostatin receptor expression in lung cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(11):1682-7.
1993: Pinski J; Halmos G; Szepeshazi K; Schally A V
Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Cancer 1993;72(11):3263-70.
1993: Pinski J; Schally A V; Halmos G; Szepeshazi K
Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
International journal of cancer. Journal international du cancer 1993;55(6):963-7.
1993: Pinski J; Halmos G; Shirahige Y; Wittliff J L; Schally A V
Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486.
The Journal of clinical endocrinology and metabolism 1993;77(5):1388-92.
1993: Pinski J; Halmos G; Schally A V
Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
Cancer letters 1993;71(1-3):189-96.
1993: Szepeshazi K; Schally A V; Groot K; Halmos G
Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
International journal of cancer. Journal international du cancer 1993;54(2):282-9.
1993: Pinski J; Schally A V; Yano T; Szepeshazi K; Halmos G; Groot K; Comaru-Schally A M; Radulovic S; Nagy A
Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
The Prostate 1993;23(2):165-78.
1993: Halmos G; Rekasi Z; Szoke B; Schally A V
Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone.
Receptor 1993;3(2):87-97.
1992: Szepeshazi K; Schally A V; Halmos G; Groot K; Radulovic S
Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Journal of the National Cancer Institute 1992;84(24):1915-22.
1992: Janáky T; Juhász A; Rékási Z; Serfözö P; Pinski J; Bokser L; Srkalovic G; Milovanovic S; Redding T W; Halmos G
Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(21):10203-7.

Sign-in to see more